Plasmablastic lymphoma: An update

Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL...

Full description

Saved in:
Bibliographic Details
Published in:International journal of laboratory hematology 2022-09, Vol.44 (S1), p.54-63
Main Authors: Bailly, Jenique, Jenkins, Nicholas, Chetty, Dharshnee, Mohamed, Zainab, Verburgh, Estelle R., Opie, Jessica J.
Format: Article
Language:English
Subjects:
aggressive lymphoma
B-cell lymphoma
Cytology
EBV
Epidemiology
Epstein-Barr virus
HIV
Human immunodeficiency virus
Immunosuppression
MYC
Myc protein
Myeloma
Non-Hodgkin's lymphoma
plasmablastic lymphoma
plasmablastic myeloma
Protein-tyrosine kinase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasmablastic lymphoma (PBL) is a highly aggressive B cell non‐Hodgkin lymphoma frequently associated with immunosuppression, particularly human immunodeficiency virus (HIV) infection. Although PBL is rare globally, South Africa has a high burden of HIV infection leading to a higher incidence of PBL in the region. Laboratory features in PBL may overlap with plasmablastic myeloma and other large B cell lymphomas with plasmablastic or immunoblastic morphology leading to diagnostic dilemmas. There are, however, pertinent distinguishing laboratory features in PBL such as a plasma cell immunophenotype with MYC overexpression, expression of Epstein–Barr virus‐encoded small RNAs and lack of anaplastic lymphoma kinase (ALK) expression. This review aims to provide a summary of current knowledge in PBL, focusing on the epidemiology, pathophysiology, laboratory diagnosis and clinical management.
ISSN:1751-5521
1751-553X
DOI:10.1111/ijlh.13863